A Phase 3 interventional study of Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT) in Liver Metastases, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by University Health Network, Toronto · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Neoplasm Metastasis by University Health Network, Toronto — 10 open to participants now, 15 under way, 2 of them phase 3. Neoplasm Metastasis · University Health Network, Toronto.
Among the 36 studies in Neoplasm Metastasis by University Health Network, Toronto, this one is the 2nd largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 3, reaches primary completion later than 14 of the 14 other live ones, and was the 32nd registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →10 of the 36 studies in Neoplasm Metastasis by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18–100 · Men only
University Health Network, Toronto · Sites in Canada
Ages 18–70
University Health Network, Toronto · Sites in Canada
Ages 18–100
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 2
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 25 across the 27 interventional studies, 48 across the 9 observational. Of the 19 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
7 of the studies in Neoplasm Metastasis by University Health Network, Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03391479University Health Network, TorontoA Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy | 2026-12-31 |
| NCT02732860University Health Network, TorontoPersonalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host | 2027-01-04 |
| NCT04243720University Health Network, TorontoImmune Resistance Interrogation Study | 2027-06 |
| NCT03364621University Health Network, TorontoComprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy | 2027-06-29 |
| NCT03712566University Health Network, TorontoMulti-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 36 studies in Neoplasm Metastasis by University Health Network, Toronto, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This international multi-centre phase 3 randomized control trial investigates whether giving a very high dose of radiation in a single treatment session (ultra-high dose: experimental) using advanced technology called MR-Linac is more effective than a high dose (control) for treating liver tumors that have spread from other parts of the body (liver metastases). This study also aims to identify predictors of treatment response and side effects by analyzing various factors such as imaging markers and genetic profiles.
Liver metastases are common in several cancers, but surgery is often not feasible for many patients. Stereotactic body radiotherapy (SBRT), which delivers focused radiation to tumors, is an alternative treatment option. Previous studies have shown promising results with SBRT, but the optimal radiation dose for liver metastases is still uncertain.
This study will look at patients with specific types of primary cancers known to respond well to SBRT. Treatment effectiveness will be assessed by monitoring tumor control, overall survival, and quality of life.
By comparing ultra-high dose SBRT with standard high dose, the study aims to determine if the former can provide better tumor control with fewer side effects. If successful, this approach could offer a significant advancement in the treatment of liver metastases, potentially improving outcomes and quality of life for patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Magnetic resonance (MR)-guided stereotactic ablative single-fraction with high dose radiation (27Gy)
Radiation: Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)
Magnetic resonance (MR)-guided stereotactic ablative single-fraction with ultra-high dose radiation (38Gy)
Radiation: Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)
Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.
Local control (LC) of treated target lesion compared to high dose MR-guided stereotactic single-fraction radiation.
The primary endpoint is LC defined as time from randomization to local failure of the treated target lesion. The LC will be estimated by cumulative incidence function with death and/or progression outside the treated target lesion (without local failure) as competing risk factors.
Time frame: 5 years
Overall survival (OS)
Endpoints related to patterns of failure, disease control, and survival will be determined by study investigators using standard-of-care imaging and clinical surveillance.
Time frame: 5 years
Progression free survival (PFS)
Endpoints related to patterns of failure, disease control, and survival will be determined by study investigators using standard-of-care imaging and clinical surveillance.
Time frame: 5 years
Intra-hepatic progression
Endpoints related to patterns of failure, disease control, and survival will be determined by study investigators using standard-of-care imaging and clinical surveillance.
Time frame: 5 years
Widespread progression.
Endpoints related to patterns of failure, disease control, and survival will be determined by study investigators using standard-of-care imaging and clinical surveillance.
Time frame: 5 years
Physician-assessed toxicities: National Cancer Institute (NCI) Common Terminology Criteria of Adverse Events (CTCAE) V.5.
Acute and late toxicities of treatment will be evaluated by CTCAE V5.0. The cumulative proportions of patients with at least one moderate to severe (grade 3-5) acute or late RT-related toxicity, measured by CTCAE (v5.0), will be compared between arms.
Time frame: 5 years
Patients-reported toxicity: Patient Reported Outcomes - Common Terminology Criteria of Adverse Events (PRO CTCAE) V.1.
Acute and late toxicities of treatment will be evaluated by PRO CTCAE (v1.0). The cumulative proportions of patients with at least one moderate to severe (grade 3-5) acute or late RT-related toxicity, measured by PRO CTCAE (v1.0), will be compared between arms.
Time frame: 5 years
Quality of life (QOL): European Organization for Research and Treatment of Cancer Quality of Life Questionnaires, Core 15 for Palliative Care (EORTC QLQ-C15-PAL)
Acute and late toxicities of treatment will be evaluated by QOL (for English-speaking eligible patients) will be measured using the EORTC QLQ-C15-PAL, which will be administered before and after treatment. Scores of all domains of the EORTC questionnaires for each treatment arm will be evaluated before and after treatment.
Time frame: Prior to treatment and after treatment up to 5 years.
Quality of life (QOL): European Organization for Research and Treatment of Cancer Quality of Life Questionnaires, liver metastases (EORTC QOQ-LM21).
Acute and late toxicities of treatment will be evaluated by QOL (for English-speaking eligible patients) will be measured using the EORTC QOQ-LM21, which will be administered before and after treatment. Scores of all domains of the EORTC questionnaires for each treatment arm will be evaluated before and after treatment.
Time frame: Prior to treatment and after treatment up to 5 years.
Changes in the levels of circulating biomarkers (cell-free tumor DNA) in response to SBRT.
Correlation analysis to determine the association between dynamic changes in biomarker levels and tumor response to SBRT and clinical outcomes. Biomarker analyses will be exploratory, involving various techniques such as quantitative analysis of circulating tumor DNA.
Time frame: Before treatment, at 1 and 3 months post SBRT, and at disease progression
Changes in the levels of circulating biomarkers (cytokines) in response to SBRT.
Correlation analysis to determine the association between dynamic changes in biomarker levels and tumor response to SBRT and clinical outcomes. Biomarker analyses will be exploratory, involving electrochemiluminescence assays for cytokine analysis.
Time frame: Before treatment, at 1 and 3 months post SBRT, and at disease progression
Changes in the levels of circulating biomarkers (metabolites) in response to SBRT.
Correlation analysis to determine the association between dynamic changes in biomarker levels and tumor response to SBRT and clinical outcomes. Biomarker analyses will be exploratory, involving liquid chromatography/mass spectrometry for metabolomics profiling.
Time frame: Before treatment, at 1 and 3 months post SBRT, and at disease progression
Changes in the levels of circulating biomarkers (immune cell populations) in response to SBRT.
Correlation analysis to determine the association between dynamic changes in biomarker levels and tumor response to SBRT and clinical outcomes. Biomarker analyses will be exploratory, involving flow cytometry analysis.
Time frame: Before treatment, at 1 and 3 months post SBRT, and at disease progression
Identification of MR imaging biomarkers in response to SBRT.
Assessed through analysis of radiomic features from diagnostic and radiation therapy imaging datasets using MRI imaging analysis software.
Time frame: 5 years
Started Dec 2024 (actual). Primary completion is estimated for Sep 2031, 81 months after the start.
Of 55 non-industry phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 108. This study's planned 81 months is above that.
Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →